Loading
A phase 3 trial of Zoldonrasib, Pembrolizumab, Pemetrexed in non-small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC is a phase 3 interventional study registered as NCT07777822 by Revolution Medicines, Inc., with 430 participants planned, started 2026-08-14 and due to reach its primary completion in 2029-10. Interventions recorded: zoldonrasib, Placebo, pembrolizumab, pemetrexed + cisplatin /carboplatin. Conditions listed: NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares KRAS & RAS inhibitors, Pemetrexed, Cisplatin, Carboplatin.
Shares KRAS & RAS inhibitors, Pemetrexed, Cisplatin, Carboplatin.
Shares Revolution Medicines, Pemetrexed, Cisplatin, Carboplatin.
Shares KRAS & RAS inhibitors, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Cytotoxic chemotherapy.
Shares KRAS & RAS inhibitors, Pemetrexed, Cisplatin, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/